Company intelligence / Profile preview

WPDC

Ownership: Private
Development stage: Other

Overview

As of June 2025, WPD Pharmaceuticals Inc. has no active business operations. Its only asset consists of shares (~7%) in its former Polish subsidiary, which continues to focus on R&D for biological compounds and small molecules targeting brain glioma and other CNS cancers. The parent company lost control of the Polish entity in November 2022 due to restructuring.[1]

Therapeutic areas: Oncology
Modalities: Small moleculeBiologicBiological compoundChemical molecule
Industry: Investors

Beyond the preview

Go deeper on WPDC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WPDC.

Explore the full profile